Clinical Observation of Chinese Medicine Treatment on Secondary Dysmenorrhoea Associated with Endometriosis

Chi Eung Danforn Lim*1,2 MBBS
Xin Lin Zhan1 BMed
Xi Ping Luo2,3 BMed
Felix Wu Shun Wong4 MD

1. Division of Chinese Medicine, School of Health Sciences, RMIT University, Melbourne, Australia
2. Guangdong Women’s & Children’s Hospital, Guangzhou, China
3. Guangzhou Medical University, Guangzhou, China
4. School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia

ABSTRACT

Background: Secondary dysmenorrhoea associated with endometriosis affects many women and is the leading cause of work and school absenteeism, with considerable impact on quality of life. This study evaluates the possible role of Chinese medicinal herbs in relieving the menstrual pain associated with endometriosis. Methods: A prospective clinical observational pilot study involving twenty-five patients with endometriosis with Chinese medical diagnosis of stagnation of qi and blood who were recruited at the Guangdong Women’s and Children’s Hospital during the period of January 2004 to December 2006 to participate in a three-month Chinese medicinal herbs study. Results: Sixteen patients reported nil dysmenorrhoea during the treatment period. The mean CA125 at the study entry was 59.67 ±28.32 u/ml, compared to 34.83 ±16.34 u/ml post-treatment. The positive EMAb before the commencement of treatment was noted in 22 of 25 cases (88%), while 5 of 25 cases (20%) remained positive after treatment. Conclusion: Short-term administration of Chinese medicinal herbs may be effective in alleviating secondary dysmenorrhoea associated with endometriosis in qi and blood stagnation pattern. It may provide an alternative treatment option for the management of pelvic pain associated with endometriosis and further research in the area is required.

KEYWORDS endometriosis, Chinese medicine, Chinese medicinal herbs, dysmenorrhoea, pelvic pain, treatment.

Introduction

Endometriosis is defined by the European Society of Human Reproduction and Embryology (ESHRE) as the ‘presence of endometrial like tissue outside the uterus’.1 As ESHRE guidelines state, endometriomas ‘may involve the uterosacral ligaments, vagina, bowel, bladder or ureters’.1 Even though a large number of studies in endometriosis has been done in western medicine, the incidence, aetiology, pathological development and optimal treatment of endometriosis remain controversial. Deligeorgiou writes that ‘the cause of menstrual cramps and associated symptoms in primary dysmenorrhoea is related to prostaglandin production. In secondary dysmenorrhoea, there is documented pelvic pathology that causes the painful menstrual cramps, and treatment is cause related.’2
Pain is the most common symptom associated with endometriosis and approximately 75% of symptomatic patients experience pelvic pain and/or dysmenorrhoea. Patients with endometriosis experience chronic pelvic pain which is worse during menstruation or at ovulation; dysmenorrhoea; subfertility; deep dyspareunia; cyclical bowel or bladder symptoms; abnormal menstrual bleeding; and chronic fatigue.

CA125
CA125 is the ovarian cancer antigen. As Muyldermans stated, ‘in normal women, plasma concentrations of CA125 are increased slightly at ovulation and significantly during menstruation. Plasma concentrations of CA125 are markedly elevated in women with cystic ovarian endometriosis and/or deeply infiltrating endometriosis.’ The clinical correlation between the value of CA125 to the diagnosis of endometriosis has been studied extensively. Studies have suggested that women with endometriosis often have high (greater than 35 IU/ml) serum CA125 concentrations.

EMAb
In addition to being a gynaecological condition, endometriosis is considered to be an autoimmune disease. Several studies suggest that there is a correlation between anti-endometrial antibodies (EMAb) and endometriosis. EMAb was found in the peritoneal fluid of patients with endometriosis through methods like passive hemagglutination, immunodiffusion, western blot, immunofluorescence, immunohistochemical, and enzyme-linked immunosorbent assays. This study aimed to evaluate the possible role of Chinese medicinal herbs in relieving the menstrual pain associated with endometriosis. A prospective clinical observational pilot study was employed. Rather than only measuring physical symptoms of relief as in many other studies, quantitative items of CA125 and EMAb were also used in our study.

Methods
From January 2004 to December 2006, twenty-five cases of laparoscopic confirmed endometriosis, diagnosed with Chinese medicine syndrome differentiation of stagnation of qi and blood, consented to take part in this Chinese medicinal herbs study at the Department of Gynaecology, Guangdong Women’s and Children’s Hospital.

All patients were tested for CA125 (Abbott testing kit) and Antiendometrial Antibody (EMAb) (Mercury Interactive testing kit) before and after treatments. 5 ml of blood in a plain tube was obtained from each subject to test for CA125 by immunoassay. Sera from subjects involved were tested by cell enzyme-linked immunosorbent assay (ELISA) for EMAb.

A four-point categorical pain intensity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) and a 10 cm visual analog scale (VAS) were used to assess the pain intensity of dysmenorrhoea reported before and during treatment periods. Patients were asked to complete the pain intensity scale and VAS at the follow-up visits. Clinic visits were scheduled at screening, once a week for the duration of the three-month treatment, and once a month during the three-month follow-up period. Adverse events were recorded throughout the study.

Inclusion and Exclusion Criteria
To be eligible for the study, patients were required to have a history of regular 28-day menstruation cycle (±7 days). In addition, patients also needed to have at least four clinical presentations of premenstrual abdominal discomfort, abdominal bloating sensation, intermittent pelvic pain, dysmenorrhoea, dyspareunia, menstrual bleed with clots, or breast tenderness. In order to fulfil the Chinese medicine diagnosis of stagnation of qi and blood, potential subjects were required to have purplish tongue with white coating and string taut pulse on palpation. Patients recruited must have been otherwise healthy, with a negative serum pregnancy test at the time of enrolment. They were also required to use a barrier contraceptive method during the study period and should not have used any oral contraception in the six months before study entry or during the study.

Patients were excluded from the study if they had a known history of diabetes mellitus, hypertension, cardiovascular disease or systemic disease; were using a hormonal implant in the six months prior to screening or an injectable or intrauterine contraceptive system within three months of screening and during the study; had abnormal results noted from full blood count, kidney function and liver function tests. In order to avoid confounding results, recruited subjects were asked to refrain from taking any form of analgesia during the treatment period.

Treatment
Patients meeting the eligibility criteria received Shengdihuang (Radix Rehmanniae) 12 g, Danggui (Radix Angelicae sinensis) 12 g, Chihsiao (Radix Paronyiae rubrae) 15 g, Chanxiong (Radix Ligustici wallichii) 10 g, Taoren (Semen Pruni persicae) 10 g, Honghua (Flos Carthami) 10 g, Chaiba (Radix Bupleuri) 12 g, Zhike (Fructus Citri aurantii) 12 g, Danshen (Radix Salviae miltiorrhizae) 30 g, and Huangqi (Radix Astragali) 10 g, one week after the diagnostic laparoscopy for ongoing pelvic pain, dysmenorrhoea and dyspareunia. For patients who were menstruating during the treatment period, Puhuang (Pollen Tiphhae) 10 g and Wulingzhi (Excrementum Trogopteri seu pteroni) 15 g were added to the formula. All patients were
asked to take the herb concoction twice a day for three months and were followed up for improvements on a monthly basis for three months after the cessation of treatment. All herbs were cooked for 30 minutes duration after boiling and the cooking procedures were uniformly carried out at the hospital central pharmacy. Patients were given individual packages of herb concoction.

Results

All 25 patients who completed the screening received treatments. Paired t-tests were used to assess the significance for pain-related outcome measures, CA125 and EMAb. The mean age of patients was 34.5 years old. According to the revised American Society of Reproductive Medicine (r-ASRM) classification, there were 9 cases in Stage I–II, 12 cases in Stage III and 9 cases in Stage IV. Sixteen out of 25 patients (64%) reported no experience of dysmenorrhoea during the treatment period. The results were consistent in the four-point categorical pain intensity scale and the 100 mm visual analog scale (VAS) (Tables 1 and 2). The mean VAS before the treatment was 7.04 ±1.98 while reduced to 1.68 ±2.88 after the conclusion of treatment (p < 0.05). As illustrated in Table 3, the mean CA125 level before treatment was 59.67 ±28.32 u/ml, compared with 34.83 ±16.34 u/ml post-treatment (p < 0.05). The positive EMAb before the commencement of treatment was noted in 22 cases (88%) while 5 cases (20%) (p < 0.05) remained positive after the treatment.

There were no reported adverse events related to the intake of Chinese medicines throughout the study and follow-up period.

Discussion

The prevailing western medical symptomatic treatment for endometriosis is expectant therapy. However, it is considered ineffective, as the recurrence rate is up to 70%. Even though surgical therapy can relieve pelvic pain, the recurrence rate is still 30–40% four weeks after the surgery was performed. Given the existing limitations and high recurrence rate in western medical treatment on endometriosis, it is important to seek alternative therapies which may have a role in alleviating the symptoms for women with endometriosis.

As mentioned, women with endometriosis often have elevated (greater than 35 IU/ml) level of serum CA125. In a study that assessed 685 women with endometriosis, the CA125 level was noted at 19, 40, 77, and 182 IU/ml for Stage I, II, III and IV disease respectively. Even though serum CA125 is not a

<table>
<thead>
<tr>
<th>TABLE 1 Pain Intensity</th>
<th>No Pain (PI = 0)</th>
<th>Mild pain (PI = 1)</th>
<th>Moderate pain (PI = 2)</th>
<th>Severe pain (PI = 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before treatment</td>
<td>0</td>
<td>8</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>At the conclusion of treatment</td>
<td>16</td>
<td>4</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 2 Pain Intensity of Dysmenorrhoea (VAS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Before treatment</td>
</tr>
<tr>
<td>At the conclusion of treatment</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 3 Serum CA125 and Antiendometrial Antibody measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA125 (IU/ml) No. of EMAb* positive cases</td>
</tr>
<tr>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Before treatment</td>
</tr>
<tr>
<td>At the conclusion of treatment</td>
</tr>
</tbody>
</table>

* EMAb = Endometrial Antibody
sensitive indicator for endometriosis, it is shown to correlate in women with endometriosis Stage III and IV disease. In our study, both EMAb and CA125 concentrations were reduced at the conclusion of treatment period. It is consistent with our initial hypothesis that Chinese herbal therapy may have a role in offering alternative care to women with endometriosis-related dysmenorrhoea.

One of the major issues among all types of clinical care is the compliance of treatment. We aimed to reduce the potential compliance and drop-out problems in this study by asking recruited patients to be reviewed once a week in the clinic.

The liver (dun), thoroughfare vessel (chong mai) and conception vessel (ren mai) govern the physiology of menstruation. The smooth running of blood and qi are responsible for normal menstruation to occur. This also relies on the free flow of liver qi and qi of chong mai. Endometriosis in Chinese medicine may be related to stagnation of qi and blood as in painful menstruation. The formula used in this study consists of various herbal components. Danggui (Radix Angelicae sinensis), Chuanxiong (Radix Ligustici wallichii) and Chishao (Radix Paeoniae rubrae) were used to nourish and invigorate the blood. Danggui is a commonly known Chinese herb that has traditionally been used to treat dysmenorrhoea, irregular menstruation, and as a supportive herb for menopausal complaints.35 Danggui is also believed to enhance the production of endogenous oestrogen.35 Further study is needed to investigate the synergistic mechanism of action of Danggui in endometriosis treatment. For patients who were menstruating during the treatment period, Puhsang (Pollen Typhae) 10 g and Wulingzhi (Excrementum Trogopteri seu pteroni) 15 g were added to the formula. Both Puhsang and Wulingzhi enter the Liver meridian and disperse the blood stasis associated with menstruation.

Flower et al.36 included two randomised clinical trials (altogether 158 subjects) in their Cochrane systematic review of Chinese herbal medicine for endometriosis. So far there has been no placebo-controlled clinical trial for evaluating the safety and effectiveness of Chinese medicine in endometriosis treatment. Furthermore, as Flower et al.36 state in their review, ‘the two trials included in this review are of poor methodological quality so these findings must be interpreted cautiously.’ Despite the fact that there were no statistical differences between Chinese herbal medicine and comparison groups in terms of symptom relief and pregnancy rate, both included studies revealed 100% symptom improvement as reported by participants. Flower et al.36 state, ‘Post-surgical administration of CHM may have comparable benefits to gestrinone but with fewer side effects. Oral CHM may have a better overall treatment effect than danazol.’ In contrast to other Chinese herbal medicine studies on endometriosis, our study also attempted to incorporate quantitative measures (CA125 and EMAb) in outcome assessments, in addition to the routine physical symptoms measurement. These measurement items will hopefully provide for objective assessment of the outcomes.

Even though we have obtained encouraging result from this pilot study, there are many areas for improvements regarding study design for future investigations. We consider the number of recruited subject to be fairly small in this study. Although it may be enough for a pilot study, a larger sample size in a blinded controlled study would be needed to evaluate the efficacy of Chinese herbs in relieving secondary dysmenorrhoea in endometriosis. In addition, a properly designed randomised controlled study in this area is certainly in need, as suggested by Flower et al. in their Cochrane review. Even though we have used CA125 and EMAb as quantitative outcome measures in our study, quality of life measurements should also be incorporated into any future study to assess whether Chinese herbal medicine can play a role in that aspect for women with endometriosis.

Conclusion
Short-term administration of Chinese medicinal herbs may be effective in alleviating secondary dysmenorrhoea associated with endometriosis in qi and blood stagnation pattern. It may provide an alternative treatment option for the management of pelvic pain associated with endometriosis, but further research into the area is needed. In order to evaluate the role of Chinese herbal medicine treatment as an adjuvant therapy in existing western medical treatment, properly designed placebo-controlled randomised integrative medicine trials are needed.

Clinical Commentary
Short-term administration of Chinese medicinal herbs may be effective in alleviating secondary dysmenorrhoea associated with endometriosis in qi and blood stagnation pattern. In addition to clinical assessment of physical symptoms improvement, quantitative measurement items (e.g., EMAb) should be taken into consideration.

References


